Menu
Innovation Observatory > Reports > Drugs > Durvalumab (Imfinzi) monotherapy for advanced or metastatic non-small cell lung cancer (EGFR and ALK wild type) – first line

< Back

Durvalumab (Imfinzi) monotherapy for advanced or metastatic non-small cell lung cancer (EGFR and ALK wild type) – first line

Drugs

Cancer and Palliative Care

August 2017


Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. It is more common in older people and is primarily linked to smoking. There are several different types of NSCLC. While chemotherapy is still the main treatment option for most people with NSCLC, some targeted treatments have been developed for people with a particular gene mutation (e.g. EGFR and ALK mutations).
Durvalumab is a new drug which is delivered directly into the bloodstream. It is being trialled in people who have NSCLC which has advanced locally (in the lungs) or has spread to other parts of the body. One clinical trial focuses on patients who do not have either an EGFR or an ALK gene mutation and therefore cannot receive treatments targeted for patients with those gene mutations. If licensed, durvalumab could provide a new treatment alternative to chemotherapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information



Load More Related Posts
Get Alerts